ReviewJournal of neurology2021
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Suicide Ideation, Attempts, and Mortality in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
- Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.Journal of neurology · 2021Pooled it
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Predictors of secondary progressive multiple sclerosis in a real word retrospective cohort: the role of clinical factors and disease-modifying therapy patterns.Acta neurologica Belgica · 2026Article
- Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients.Bioengineering (Basel, Switzerland) · 2026Article
- Predicting disease progression in multiple sclerosis with clinically accessible information and technology.Journal of neurology · 2026Article
- Structural Characterization, Toxicity Assessment and Molecular Modeling of Forced Degradation Products of Siponimod.International journal of molecular sciences · 2026Article
- Patient-reported gradual worsening reveals progression beyond MS subtypes.Journal of neurology · 2026Article
- Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.Molecular biomedicine · 2026Review
- Health-related quality of life of patients with multiple sclerosis in China: a national online survey.Health and quality of life outcomes · 2025Article
- Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- The Role of MRI Lesions in Identifying Secondary Progressive Multiple Sclerosis: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.Pharmacological reports : PR · 2025Article
- The impact of changing diagnostic criteria on disability in a Brazilian multiple sclerosis cohort.Arquivos de neuro-psiquiatria · 2025Article
- Fluid Biomarkers in Demyelinating Spectrum Disorders: Past, Present, and Prospects.International journal of molecular sciences · 2025Review
- Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Species-specific optimization of oxylipin ionization in LC-MS: a design of experiments approach to improve sensitivity.Analytical and bioanalytical chemistry · 2025Article
- Suicidal Ideation in Patients With Multiple Sclerosis and Its Association With Clinical and Demographic Characteristics.Brain and behavior · 2025Article
- Accelerometry-Assessed Physical Activity and Circadian Rhythm to Detect Clinical Disability Status in Multiple Sclerosis: Cross-Sectional Study.JMIR mHealth and uHealth · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will develop SPMS within 15 years and up to two-thirds after 30 years, leading to a progressive decrease of neurological function and limitation of daily activities. Nevertheless, the SPMS diagnosis is often established retrospectively and delayed up to 3 years due to several patient- and clinician-related factors. Definitive clinical diagnostic criteria are lacking and research is currently ongoing to identify imaging and biochemical biomarkers. As new therapies are introduced, early SPMS diagnosis may represent a window of opportunity for intervention. New approaches, endpoints or technologies could help physicians establishing a diagnosis. Here, we review SPMS in relation to its diagnostic and definition challenges and current screening techniques and tools.
Indexed as
Identifiers
31363847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.